Dr. Patrick Geraghty discusses how this strengthens the approach and how the Tack allows for more aggressive treatment options when treating below the knee disease.
I think it really is going to augment an aggressive approach to be DK disease. We have been missing that critical piece of scaffolding beyond the niche use of off label coronary stents and the very proximal segments of the tibial vessels. And I think the results of this are excellent. We're seeing patent see rates in 87% at six months that are just superb. And so that allows us to, I think, more aggressively sized angioplasty to the tibial vessels. I think the tibial interventions suffer from chronic under sizing. So to get better, Luminal gain to pursue more aggressive recapitalization techniques that may result in some dissection flaps with the knowledge that we can then restore potency and tack up those flaps appropriately. So I think this will really increase our overall level of aggressiveness in treating table disease. Yeah,